

Chlorocresol: An Activator of Ryanodine Receptor-Mediated Ca^{2+} Release

FRANCESCO ZORZATO, ERICA SCUTARI, VINCENZO TEGAZZIN, EMILIO CLEMENTI, and SUSAN TREVES

Institute of General Pathology, University of Ferrara, 44100 Ferrara, Italy (F.Z., S.T.), Unita' Sanitaria Locale 21, Ospedale Ortopedico e Traumatologico, Servizio di Anestesia e Rianimazione, 35100 Padova, Italy (E.S., V.T.), and Faculty of Pharmacy, University of Reggio Calabria, Catanzaro, CNR Cytopharmacology Center, Dibt H. San Raffaele Scientific Institute, 20132 Milano, Italy (E.C.)

Received June 16, 1993; Accepted September 9, 1993

SUMMARY

In the present study we investigated the effect of the compound chlorocresol on intracellular Ca^{2+} homeostasis. Three different systems that have been shown to express the ryanodine receptor Ca^{2+} channel were chosen, i.e., skeletal muscle sarcoplasmic reticulum, cerebellar microsomes, and PC12 cells. In skeletal muscle sarcoplasmic reticulum, 4-chloro-*m*-cresol was found to be a potent activator of Ca^{2+} release mediated by a ruthenium red/caffeine-sensitive Ca^{2+} release channel. In cerebellar microsomes, this compound released Ca^{2+} from an inositol-1,4,5-trisphosphate-insensitive store, suggesting that there too it was

acting at the ryanodine receptor level. When tested on PC12 cells, chlorocresol released Ca^{2+} from a caffeine- and thapsigargin-sensitive intracellular store. In addition, the compound was capable of releasing Ca^{2+} after pretreatment of PC12 cells with bradykinin, suggesting that it acts on a channel contained within an intracellular Ca^{2+} store that is distinct from that sensitive to inositol-1,4,5-trisphosphate. Structure-activity relationship analyses suggest that the chloro and methyl groups in chlorocresols are important for the activation of the ryanodine receptor Ca^{2+} release channel.

The RYR is a homotetramer of four 565-kDa subunits that mediates Ca^{2+} release from intracellular stores (1-3). The primary sequence of this protein has been determined from a number of species and tissues (1, 2, 4-7); Northern blot analyses demonstrated that at least three isoforms exist, one specific for skeletal muscle, one present in cardiac muscle, and a third present in brain. Analysis of the predicted primary structure of the RYR protomer indicates that the amino-terminal portion constitutes a large hydrophilic domain, whereas the last 1000 amino acids form the channel itself (1, 2).

A large number of chemically diverse substances have been reported to release calcium from isolated TC via the RYR Ca^{2+} channel. *In vitro*, caffeine, Ca^{2+} itself, Ag^{2+} , thymol, halothane, doxorubicin, and ryanodine (8, 9) all release Ca^{2+} by stimulating the SR RYR. To explain the molecular mechanism by which such diverse substances can act on the same molecule, one can postulate the presence of multiple activator binding sites present on the large hydrophilic portion of the receptor. This region must control a membrane-bound structure encompassing the

ion-permeable channel (10). Thus, *in vivo* the RYR could be the target of chemical substances present as additives or preservatives in a variety of drug formulations.

MH, an inherited pharmacogenetic disorder, has been linked to a mutation in the RYR molecule (11). Halothane and other halogenated agents, as well as succinylcholine, have been reported to trigger MH (12, 13). As part of a comprehensive study on MH-inducing compounds, we tested the capacity of pharmacological additives to stimulate contraction of isolated muscle bundles. We found that chlorocresol, a preservative routinely added to commercial preparations of succinylcholine, is in fact a strong activator of muscle contraction.¹

Here we demonstrate that chlorocresol is capable of releasing Ca^{2+} from a ruthenium red/caffeine-sensitive Ca^{2+} release channel selectively localized in TC. Furthermore, chlorocresol is capable of releasing Ca^{2+} from heparin-treated cerebellar microsomes, indicating that it is not acting via the Insp_R . Finally, we show that in PC12 cells this agonist releases Ca^{2+} from a caffeine/thapsigargin-sensitive intracellular store.

This work was supported by Grants 30 and 185 from Telethon-Italy and Grant CNR 92.02256 and Ministero della Università e della Ricerca Scientifica e Tecnologica, fondi 40% e 60% to Prof. G. Benassi and P. Melandri.

¹ V. Tegazzin, E. Scutari, S. Treves, and F. Zorzato. Chlorocresol induces contracture of malignant hypothermic susceptible muscles. Manuscript in preparation.

ABBREVIATIONS: RYR, ryanodine receptor; TC, terminal cisternae; SR, sarcoplasmic reticulum; MH, malignant hyperthermia; Insp_R , inositol-1,4,5-trisphosphate receptor; PMSF, phenylmethanesulfonyl fluoride; $[\text{Ca}^{2+}]_\text{i}$, intracellular Ca^{2+} concentration; $[\text{Ca}^{2+}]_\text{o}$, extracellular Ca^{2+} concentration; Insp_3 , inositol-1,4,5-trisphosphate; EGTA, ethylene glycol bis(β -aminoethyl ether)-*N,N,N',N'*-tetraacetic acid; HEPES, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid; LSR, longitudinal sarcoplasmic reticulum; MOPS, 3-(*N*-morpholino)propanesulfonic acid.

Thus, chlorocresol could become a new pharmacological tool with which to study intracellular Ca²⁺ homeostasis.

Experimental Procedures

Materials. The experiments presented here were carried out on the parental PC12 line subcultured in our laboratory as described previously (14). Ruthenium red, 4-chloro-*m*-cresol, 4-chloro-*o*-cresol, *o*-cresol, *p*-chlorophenol, and antipyrilazo III were from Fluka (Buchs, Switzerland); bradykinin, heparin, and caffeine were from Sigma Chemical Co. (St. Louis, MO); Ca²⁺ ionophores A23187 and ionomycin were from Calbiochem (San Diego, CA); fura-2 and fluo-3 were from Molecular Probes (Eugene, OR); and InsP₃ was from ICN (Costa Mesa, CA). All other materials were analytical grade or of the highest available grade. Thapsigargin was a kind gift of Prof. Tullio Pozzan, Institute of General Pathology, University of Padova (Padova, Italy).

Subcellular fractionation. SR was isolated from white muscles of New Zealand White rabbits and was fractionated into longitudinal tubules and TC in the presence of antiproteolytic agents as described by Saito *et al.* (15). The SR fractions were resuspended in 0.3 M sucrose, 5 mM imidazole, pH 7.4, 100 μM PMSF, 1 μg/ml leupeptin (buffer A), and were stored in liquid nitrogen until used.

Bovine cerebella were obtained from the local slaughterhouse, from freshly slaughtered animals. The microsomal fraction was obtained by homogenizing the tissue in 0.3 M sucrose, 5 mM imidazole, pH 7.4, 100 μM PMSF, 1 μg/ml leupeptin, as described previously (16). The 100,000 × *g* pellet was resuspended in 0.3 M sucrose, 5 mM imidazole, pH 7.4, 100 μM PMSF, 1 μg/ml leupeptin, 1 mM benzamide, and was stored in liquid nitrogen until used. Protein concentration was determined according to the method of Bradford (17), using bovine serum albumin as the standard.

Ca²⁺ measurements. Ca²⁺ release from isolated SR fractions was measured in a Beckmann DU7400 diode array spectrophotometer by monitoring the $A_{710} - A_{780}$ value of the Ca²⁺ indicator antipyrilazo III, as described by Palade (9) and detailed by Treves *et al.* (18). Pulses of 25 nmol of Ca²⁺ were administered to load the SR fractions with approximately 2.3 μmol of Ca²⁺/mg of protein. When steady state was reached, Ca²⁺ release was triggered by the addition of different compounds.

Ca²⁺ release from TC and cerebellar microsomes was measured in an LS50 thermostatted Perkin Elmer spectrofluorimeter equipped with magnetic stirring, as described by Sayers *et al.* (19). Briefly, TC (final concentration, 100 μg/ml) or microsomes (final concentration, 200 μg/ml) were added to a fluorimeter cuvette containing 7.5 mM potassium pyrophosphate, 18.5 mM MOPS, pH 7.0, 100 mM KCl, 5 mM creatine phosphate, 20 μg/ml creatine phosphate kinase, and 200 nM fluo-3 free acid. Ca²⁺ accumulation was stimulated by the addition of 1 mM MgATP. Pulses of Ca²⁺ were administered and, after steady state was reached, Ca²⁺ release was stimulated by the addition of different agents. At the end of each experiment F_{min} and F_{max} were obtained by the addition of EGTA and Ca²⁺, respectively, and [Ca²⁺] was calculated according to the formula $[Ca^{2+}] = K_d(F - F_{min}/F_{max} - F)$ ($K_d = 900$ nM) (19, 20). Loading with fura-2 and [Ca²⁺]_i measurements were carried out in 140 mM NaCl, 5 mM KCl, 1 mM MgSO₄, 20 mM HEPES, 1 mM NaHPO₄, 5 mM glucose, pH 7.4, as described (21, 22). In each experiment, 5 × 10⁵ cells/ml, loaded with 5 μM fura-2/acetoxymethyl ester, were used.

Results

Characterization of chlorocresol-induced Ca²⁺ fluxes in isolated SR fractions. Fig. 1 shows the chemical structures of the compounds used to study Ca²⁺ fluxes. In Fig. 2 the effect of 4-chloro-*m*-cresol on the initial rate of Ca²⁺ release from actively loaded longitudinal tubules (LSR) and TC vesicles is shown. Ca²⁺ fluxes were followed spectrophotometrically with the indicator antipyrilazo III, as described previously (18).




Fig. 1. Chemical structures of *o*-cresol, 4-chloro-*o*-cresol, 4-chloro-*m*-cresol, and *p*-chlorophenol.

Addition of 1 mM chlorocresol caused a rapid release of Ca²⁺ from the TC fraction (Fig. 2A), whereas it had no effect on LSR (Fig. 2B), indicating that it was not acting by inhibiting the Ca²⁺-ATPase or damaging the vesicles. To establish whether this agent acts via the RYR Ca²⁺ release channel, we examined the effect of ruthenium red, a known inhibitor of the RYR. Fig. 2C shows that pretreatment of TC with 10 μM ruthenium red completely abolished 4-chloro-*m*-cresol-induced Ca²⁺ release. Fig. 3 shows the dose-dependent effect of 4-chloro-*m*-cresol on the kinetics of Ca²⁺ release from TC. The half-maximally stimulatory dose of Ca²⁺ release was 300 μM, whereas at 900 μM this agonist released Ca²⁺ at an initial rate of approximately 4.8 μmol of Ca²⁺/min/mg of protein. Such a rate is comparable to Ca²⁺ release activated by caffeine (9).

We next studied whether compounds chemically related to chlorocresol were capable of releasing Ca²⁺. *p*-Chlorophenol at 100 μM had no effect on [Ca²⁺]_o (Fig. 4A), whereas at higher concentrations the compound was able to elicit release of Ca²⁺ (Fig. 4B); however, the release rate was approximately 10-fold lower than that observed with similar concentrations of 4-chloro-*m*-cresol. Comparison of Fig. 4, A and B, also shows that the position of the methyl group influences the Ca²⁺-releasing capacity of the compounds; 4-chloro-*m*-cresol was more potent than its *ortho*-analogue.

To further confirm the effects of chlorocresols on Ca²⁺ fluxes, we carried out similar experiments using a different Ca²⁺ indicator, namely fluo-3. In Fig. 5 we show that, at a concentration of 800 μM, *o*-cresol had no effect on [Ca²⁺]_o, whereas 800 μM 4-chloro-*m*-cresol caused a rapid release of Ca²⁺ from TC. The subsequent addition of the Ca²⁺ ionophore A23187 caused, as expected, a larger release of Ca²⁺ from *o*-cresol-treated TC than from vesicles that had received 4-chloro-*m*-cresol. We were unable to test the effect of caffeine, because its addition strongly quenched the fluorescent signal (Fig. 5).

Characterization of chlorocresol-induced Ca²⁺ fluxes in bovine cerebellar microsomes. Our experiments on isolated SR TC cannot exclude the possibility that chlorocresol is also activating the InsP₃R Ca²⁺ release channel. To address this problem we prepared microsomes from bovine cerebellum, a tissue that is rich in InsP₃R but that also contains a caffeine-sensitive Ca²⁺ release channel (23, 24). Microsomes were pre-




Fig. 2. 4-Chloro-*m*-cresol induces Ca²⁺ release from skeletal muscle TC but not LSR. The experiments were carried out as described in Experimental Procedures, using the Ca²⁺ indicator anti-pyrilazo III. Where indicated, 45 μg of TC (A and C) or LSR (B) were added to the cuvette. Five consecutive additions of 25 nmol of CaCl₂ were administered; after completion of Ca²⁺ loading, 1 mM 4-chloro-*m*-cresol (A and B) or 10 μM ruthenium red followed by 1 mM 4-chloro-*m*-cresol (C) was added. At the end of the experiments, 25 nmol of CaCl₂ were added to calibrate the dye response. Upward deflections indicate Ca²⁺ release, and downward deflections indicate Ca²⁺ accumulation.

pared as described in Experimental Procedures, and Ca²⁺ accumulation was stimulated by the addition of MgATP. Changes in [Ca²⁺]_i were followed with the fluorescent indicator fluo-3. As expected, 5 μM InsP₃ caused release of Ca²⁺ from microsomes (Fig. 6A); the subsequent addition of InsP₃ caused no additional release of Ca²⁺, whereas addition of 800 μM 4-chloro-*o*-cresol caused a small release of Ca²⁺. Fig. 6B shows that 800 μM chlorocresol was capable of releasing Ca²⁺ from microsomes. Furthermore, when microsomes were pretreated with heparin, a known inhibitor of the InsP₃R, InsP₃ failed to elicit Ca²⁺ release; on the other hand, chlorocresol was still capable of releasing Ca²⁺ (Fig. 6C). These results exclude a direct action of chlorocresol on the InsP₃R and also indicate that microsomes may contain at least three intracellular Ca²⁺-containing vesicles, i.e., a small population containing only a RYR-like Ca²⁺ release channel, another containing both channels, and a third that can be depleted only by ionophore treatment. The latter store is thapsigargin insensitive (data not shown) and may represent either resealed membrane vesicles or contaminating mitochondria. Unfortunately, we were unable to activate the

RYR Ca²⁺ release channel with caffeine or doxorubicin, because addition of both compounds strongly quenched the fluorescent signal.

Effect of chlorocresol on [Ca²⁺]_i of PC12 cells. A number of studies have documented that in the rat pheochromocytoma cell line PC12 two distinct intracellular Ca²⁺ release channels exist, one being InsP₃ sensitive and the other caffeine sensitive (14). Caffeine has thus been used to check for the presence of RYR-like Ca²⁺ channels in these as well as other cells. Unfortunately the use of this agonist has several drawbacks; (i) very high concentrations (10–40 mM) must be used to obtain an effect and (ii) at such high doses caffeine quenches fluo-3 fluorescent signals, whereas it causes fluorescence artifacts when cells are loaded with low concentrations of fura-2.² Because of the problems linked to the use of caffeine, we tested whether chlorocresol could be used to study intracellular Ca²⁺ pools. All the experiments carried out in intact cells were performed in Ca²⁺-free medium. Fig. 7 shows the effect of cresol

² S. Treves, unpublished observations.




Fig. 3. Dose dependence of 4-chloro-*m*-cresol-induced net Ca^{2+} release from skeletal muscle TC. Experiments were carried out as described for Fig. 2A, and Ca^{2+} release was stimulated by the addition of different concentrations of 4-chloro-*m*-cresol. Ca^{2+} release is expressed as the mean \pm standard error of four experiments.




Fig. 4. Ca^{2+} -releasing properties of chlorocresols and *p*-chlorophenol on isolated TC. Conditions were as in Fig. 2. Ca^{2+} release was stimulated by the addition of 4-chloro-*m*-cresol (—), 4-chloro-*o*-cresol (---), or *p*-chlorophenol (·····). Arrows, addition of 100 μM (A) or 1 mM (B) of each compound.




Fig. 5. Effects of cresols on $[\text{Ca}^{2+}]_i$ of TC. Experiments were carried out as described in Experimental Procedures, using the indicator fluo-3. Ca^{2+} accumulation was stimulated by the addition of 1 mM MgATP to isolated TC (final concentration, 100 $\mu\text{g}/\text{ml}$); three consecutive pulses of 5 μM CaCl_2 were administered to the cuvette and after steady state was reached 800 μM 4-chloro-*m*-cresol (—) or 800 μM *o*-cresol (---) was added. At the end of the experiment 5 $\mu\text{g}/\text{ml}$ A23187 was added to release the accumulated Ca^{2+} . Caffeine (10 mM) was also added (---), to show fluorescence quenching.




Fig. 6. Effects of 4-chloro-*o*-cresol on $[Ca^{2+}]_i$ of bovine cerebellar microsomes. Conditions were as described for Fig. 5; 200 μ g/ml bovine microsomes were used in each experiment. In A–C, different compounds were added (arrows) as indicated.

and its methylated derivatives on $[Ca^{2+}]_i$ homeostasis. Under these conditions *o*-cresol (Fig. 7A) had no effect on $[Ca^{2+}]_i$. On the other hand, 4-chloro-*m*-cresol (Fig. 7B) and 4-chloro-*o*-cresol (Fig. 7C) were capable of releasing Ca^{2+} from intracellular stores. The effect on $[Ca^{2+}]_i$ was completely abolished by pretreatment with 100 nM thapsigargin (Fig. 7D) or 1 μ M ionomycin (data not shown).

In Fig. 8 the dose dependence curves for 4-chloro-*m*-cresol and 4-chloro-*o*-cresol effects on $[Ca^{2+}]_i$ are given; the order of potency of the two compounds in PC12 cells is 4-chloro-*o*-cresol > 4-chloro-*m*-cresol. To rule out the possibility that these agents were indirectly affecting $[Ca^{2+}]_i$ by damaging the cell membrane, we tested their effects on membrane potential using the fluorescent dye bis-oxonol. Addition of chlorocresol had no

apparent damaging effect, because it caused plasma membrane hyperpolarization, as would be expected for an agent causing release of Ca^{2+} from intracellular stores (data not shown).

The next set of experiments were aimed at studying the effect of chlorocresol on the $InsP_3$ -sensitive and/or caffeine-sensitive intracellular Ca^{2+} pools. We observed that, in Ca^{2+} -free medium, the Ca^{2+} transients elicited by saturating concentrations of chlorocresol were drastically reduced if the cells were first exposed to caffeine (Fig. 9A). Similarly, if PC12 cells were pretreated with chlorocresol, caffeine failed to elicit an increase in $[Ca^{2+}]_i$ (Fig. 9B). On the other hand, pretreatment of PC12 cells with 200 nM bradykinin, an agonist that causes activation of $InsP_3$ -sensitive Ca^{2+} channels, did not abolish the response to 4-chloro-*o*-cresol (Fig. 9C).




Fig. 7. Effects of various cresol derivatives on $[\text{Ca}^{2+}]$ of PC12 cells. Suspensions of 0.5×10^6 PC12 cells/ml, loaded with 5 μM fura-2, were used. Experiments were performed in Ca^{2+} -free medium plus 2 mM EGTA. The results shown are representative of at least four experiments.




Fig. 8. Dose-response curves for chlorocresols in PC12 cells and effects on $[Ca^{2+}]_i$. $[Ca^{2+}]_i$ was measured in PC12 cells that had been loaded with 5 μM fura-2 and treated with different concentrations of 4-chloro-*o*-cresol (Δ) or 4-chloro-*m*-cresol (\blacksquare). $[Ca^{2+}]_i$ was obtained by subtracting the maximal $[Ca^{2+}]_i$ increase from the basal $[Ca^{2+}]_i$. Values are the mean \pm standard error of four experiments.

In the experiments shown in Fig. 10, we examined the effect of chlorocresol on PC12 cells in the presence of both bradykinin and caffeine. Bradykinin (200 nM) strongly reduced but did not abolish the increase in $[Ca^{2+}]_i$ produced by 40 mM caffeine. The subsequent addition of 4-chloro-*o*-cresol had no additional effect on $[Ca^{2+}]_i$, although ionomycin was still capable of releasing Ca^{2+} from membrane-bound intracellular stores.

Discussion

Effect of chlorocresol on $[Ca^{2+}]_i$ homeostasis. In the present study we report the effect of chlorocresol on Ca^{2+} homeostasis and demonstrate that this compound is a strong activator of the RYR Ca^{2+} release channel. Ca^{2+} release experiments with isolated SR vesicles indicate that the effect is specific for the RYR, because (i) pretreatment of TC vesicles with ruthenium red, a known inhibitor of this Ca^{2+} release channel, completely blocks the effect of chlorocresol and (ii) chlorocresol has no effect on LSR vesicles and thus its mode of action does not involve inhibition of the Ca^{2+} -ATPase, which comprises approximately 80% of the latter fraction (15), or damage to the vesicles. Chlorocresol does not activate the $InsP_3R$, because its Ca^{2+} -releasing effects on cerebellar microsomes were maintained even after blockage of the $InsP_3R$ with heparin.

In PC12 cells, a caffeine-sensitive cell line, the effect of chlorocresol could not be attributed to nonspecific damage of the membranes by the compound because, under the experimental conditions used, it did not cause plasma membrane depolarization but rather a slight hyperpolarization, a consequence of its ability to release intracellular Ca^{2+} . The kinetics of chlorocresol-induced Ca^{2+} transients are slower than those of the transients induced by bradykinin. In fact, under our experimental conditions, in the presence of the latter agonist the rise in $[Ca^{2+}]_i$ occurred within 5–10 sec and the $[Ca^{2+}]_i$ returned to basal levels within 20–30 sec. Similar transients could be obtained by addition of ionomycin. In the presence of

800 μM 4-chloro-*o*-cresol, however, peak $[Ca^{2+}]_i$ was reached after approximately 160 sec and the $[Ca^{2+}]_i$ did not return to resting levels for at least 250 sec. As far as the rising phase is concerned, the different kinetics may reflect permeability differences. In fact, bradykinin, a phosphatidylinositol-4,5-bisphosphate-mobilizing agonist, acts by stimulating surface receptors, whereas chlorocresol must pass through the plasma membrane to activate its receptor. With regard to the slower decay phase seen with chlorocresol, it is unlikely that it reflects inhibition of the microsomal Ca^{2+} -ATPase, because as mentioned earlier this compound has no apparent effect on the SR Ca^{2+} pump. The slower decay phase may be due to the extent of activation of the Ca^{2+} -ATPase (25, 26), because the activity of this enzyme is regulated by Ca^{2+} (27). Bradykinin causes a rapid increase in $[Ca^{2+}]_i$; thus, it activates the Ca^{2+} -ATPase to a greater extent than does a slower rise in $[Ca^{2+}]_i$. In this context, it should be mentioned that, when PC12 cells are pretreated with bradykinin, the chlorocresol-induced $[Ca^{2+}]_i$ rise is slower than that seen in cells receiving the latter agonist alone. This observation may reflect the fact that the Ca^{2+} content of the stores is diminished; on the other hand, it may be a consequence of preactivation of the Ca^{2+} -ATPase by bradykinin.

Use of chlorocresol to study intracellular Ca^{2+} pools. Thapsigargin, a specific inhibitor of SR/endoplasmic reticulum Ca^{2+} -ATPase-like Ca^{2+} pumps (28, 29), inhibited the chlorocresol-induced rise in $[Ca^{2+}]_i$, indicating that chlorocresol releases Ca^{2+} from a membrane-bound intracellular store equipped with a SR/endoplasmic reticulum Ca^{2+} -ATPase-type ATPase.

In PC12 cell clones, we found that (i) bradykinin did not completely abolish caffeine-mediated Ca^{2+} release; (ii) chlorocresol was consistently able to release Ca^{2+} from intracellular stores, even after treatment with bradykinin; (iii) intracellular Ca^{2+} transients caused by caffeine and chlorocresol were strongly reduced, if not abolished, upon pretreatment of the cells with either agonist; and (iv) there was an intracellular Ca^{2+} store that could be depleted only with ionomycin. The simplest way to explain these results is to postulate the existence of at least two types of intracellular Ca^{2+} stores, one containing both $InsP_3R$ and thapsigargin-sensitive RYR (14) and another that can be released only with ionomycin. If this were the case, treatment with bradykinin, which causes only a rapid release of Ca^{2+} , would partially deplete the Ca^{2+} pool and chlorocresol, which appears to be more potent than caffeine, would still be capable of releasing Ca^{2+} . The other possibility is that three types of intracellular Ca^{2+} stores exist, one equipped with both $InsP_3R$ and RYR, another equipped with only RYR, and a third that is insensitive to thapsigargin and releases Ca^{2+} only after ionophore treatment. Thus, stimulation with bradykinin, a phosphatidylinositol-4,5-bisphosphate-mobilizing agonist, would release Ca^{2+} only from vesicles containing both RYR and $InsP_3R$, whereas chlorocresol would release Ca^{2+} from both RYR/ $InsP_3R$ - and RYR-containing intracellular stores. The results obtained using bovine cerebellar microsomes confirm in part the results obtained in whole cells, because they suggest the existence of at least three populations of vesicles, one that is chlorocresol sensitive, another that is sensitive to both $InsP_3$ and chlorocresol, and a third that releases Ca^{2+} only after treatment with a Ca^{2+} ionophore.

Regarding the lack of effect of chlorocresol in PC12 cells pretreated with both bradykinin and caffeine, we can only




Fig. 9. Effects of 4-chloro-o-cresol on the intracellular Ca^{2+} pools of PC12 cells. Conditions were as in Fig. 7.




Fig. 10. Effects of 4-chloro-*o*-cresol on intracellular Ca^{2+} transients of PC12 cells in the presence of bradykinin and caffeine. Conditions were as in Fig. 7.

advance an hypothesis. The RYR is a substrate for a variety of protein kinases including protein kinase C (30), and phosphorylation of the RYR appears to inactivate channel activity (31). Prestimulation of PC12 cells with bradykinin followed by an unusually high concentration of caffeine may thus activate an inhibitory mechanism mediated by protein kinases, which would in turn down-regulate the Ca^{2+} channel response to additional Ca^{2+} -mobilizing stimuli.

Structure-activity relationship of chlorocresols. A wide variety of unrelated drugs have been shown to induce SR Ca^{2+} release (8, 9). In the present report we used cresol and its methylated derivatives and found that (i) the presence of a chloride atom plus a methyl group is necessary for the activation of Ca^{2+} release, (ii) the position of such a methyl group influences the ability of the compound to release Ca^{2+} , and (iii) skeletal RYR was more sensitive to the effect of 4-chloro-*m*-cresol, whereas in PC12 cells 4-chloro-*o*-cresol was more potent in releasing Ca^{2+} from intracellular stores.

Chlorocresol has a relatively simple chemical structure; thus, one can postulate that there are two important structural groups that confer reactivity to the molecule; a methyl group, which partitions in a hydrophobic pocket, is an electron donor and most likely renders more electronegative the chloride at position 4 of the aromatic ring. Substitution of the methyl group with a bulkier hydrophobic side chain may produce a more potent RYR agonist. It is tempting to speculate that the electronegative chloride interacts with positively charged amino acids in the RYR gating domain. This conclusion is substantiated by the finding that *o*-cresol, which lacks the chloride group, is not capable of stimulating Ca^{2+} release from either isolated TC or PC12 cells, whereas *p*-chlorophenol, which lacks the hydrophobic side chain, is approximately 10 times less potent than 4-Cl-cresol in activating Ca^{2+} release from isolated TC. *p*-Chlorophenol had no visible effect on $[\text{Ca}^{2+}]_i$ in PC12 cells; however, this compound was quite fluorescent at the fura-2 wavelengths, and thus autofluorescence artifacts may have masked small changes in $[\text{Ca}^{2+}]_i$.

Acknowledgments

We thank Prof. Francesco DiVirgilio for his suggestions and for critically reading the manuscript and Prof. Tullio Pozzan and Prof. Mario Rippa for helpful suggestions. We would also like to acknowledge Paola Menegazzi for the artwork.

References

1. Takeshima, H., S. Nishimura, H. Matsumoto, K. Ishida, N. Kangawa, H. Minamino, M. Matsuo, M. Ueda, M. Hanakoa, T. Horise, and S. Numa. Primary structure and expression from complementary DNA of skeletal muscle ryanodine receptor. *Nature (Lond.)* 339:439-445 (1989).
2. Zorzato, F., J. Fujii, K. Otsu, M. Phillips, N. M. Green, F. A. Lai, G. Meisner, and D. H. MacLennan. Molecular cloning of cDNA encoding human and rabbit forms of the Ca^{2+} release channel (ryanodine receptor) of skeletal muscle sarcoplasmic reticulum. *J. Biol. Chem.* 265:2244-2256 (1990).
3. Lai, F. A., H. P. Erickson, E. Rousseau, Q. Y. Liu, and G. Meisner. Purification and reconstitution of the calcium release channel from skeletal muscle. *Nature (Lond.)* 331:315-319 (1988).
4. Otsu, K., H. F. Willard, V. J. Khanna, F. Zorzato, N. M. Green, and D. H. MacLennan. Molecular cloning of cDNA encoding the Ca^{2+} release channel (ryanodine receptor) of rabbit cardiac muscle sarcoplasmic reticulum. *J. Biol. Chem.* 265:13472-13483 (1990).
5. Hakamata, Y., J. Nakai, H. Takeshima, and K. Imoto. Primary structure and distribution of a novel ryanodine receptor calcium release channel from rabbit brain. *FEBS Lett.* 312:229-235 (1992).
6. Nakai, J., T. Imagawa, Y. Hakamata, M. Shigekawa, H. Takeshima, and S. Numa. Primary structure and functional expression from cDNA of the cardiac ryanodine receptor calcium release channel. *FEBS Lett.* 271:169-177 (1990).
7. Giannini, G., E. Clementi, R. Ceci, G. Marziani, and V. Sorrentino. Identification of a broadly expressed ryanodine receptor Ca^{2+} channel regulated by TGF β . *Science (Washington D. C.)* 257:91-94 (1992).
8. Palade, P., C. Dettbarn, D. Brunder, P. Stein, and G. Hals. Pharmacology of calcium release from sarcoplasmic reticulum. *J. Bioenerg. Biomembr.* 21:295-320 (1989).
9. Palade, P. Drug-induced Ca^{2+} release from isolated sarcoplasmic reticulum. II. Release involving a Ca^{2+} -induced Ca^{2+} release channel. *J. Biol. Chem.* 262:6142-6148 (1987).
10. Kim, D. H., S. T. Ohnishi, and N. Ikemoto. Kinetic studies of calcium release from sarcoplasmic reticulum *in vitro*. *J. Biol. Chem.* 258:9662-9668 (1983).
11. Fujii, J., K. Otsu, F. Zorzato, S. DeLeon, V. J. Khanna, J. E. Weiler, P. J. O'Brien, and D. H. MacLennan. Identification of a mutation in porcine ryanodine receptor associated with malignant hyperthermia. *Science (Washington D. C.)* 253:448-451 (1991).
12. Gronert, G. A. Malignant hyperthermia. *Anesthesiology* 53:395-423 (1980).
13. Sealer, D. I. Malignant hyperthermia. *J. Pediatr.* 109:9-13 (1986).
14. Zacchetti, D., E. Clementi, C. Fasolato, P. Lorenzoni, M. Zottini, F. Grohovaz, G. Fumagalli, T. Pozzan, and J. Meldolesi. Intracellular Ca^{2+} pools in PC12 cells: a unique rapidly exchanging pool is sensitive to both inositol 1,4,5-trisphosphate and caffeine-ryanodine. *J. Biol. Chem.* 266:20152-20158 (1991).
15. Saito, A., S. Seiler, A. Chu, and S. Fleischer. Preparation and morphology of

- SR terminal cisternae from rabbit skeletal muscle. *J. Cell Biol.* **99**:875-885 (1984).
16. Treves, S., M. DeMattei, M. Lanfredi, A. Villa, N. M. Green, D. H. MacLennan, J. Meldolesi, and T. Pozzan. Calreticulin is a candidate for a calsequestrin-like function in Ca²⁺ storage compartments (calciosomes) of liver and brain. *Biochem. J.* **271**:473-480 (1990).
 17. Bradford, M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Anal. Biochem.* **72**:248-254 (1976).
 18. Treves, S., P. Chiozzi, and F. Zorzato. Identification of the domain recognized by anti-(ryanodine receptor) antibodies which affect Ca²⁺-induced Ca²⁺ release. *Biochem. J.* **291**:757-763 (1993).
 19. Sayers, L. G., G. R. Brown, R. H. Mitchell, and F. Michelangeli. The effects of thimerosal on calcium uptake and inositol 1,4,5-trisphosphate-induced Ca²⁺ release by cerebellar microsomes. *Biochem. J.* **289**:883-887 (1993).
 20. Minta, A., J. P. Y. Kao, and R. Y. Tsien. Fluorescent indicators of cytosolic calcium based on rhodamine and fluorescein chromophores. *J. Biol. Chem.* **264**:8171-8178 (1989).
 21. Grynkiewicz, G., M. Poenie, and R. Y. Tsien. A new generation of Ca²⁺ indicators with greatly improved fluorescence properties. *J. Biol. Chem.* **260**:3440-3446 (1985).
 22. Treves, S., F. DiVirgilio, V. Cerundolo, P. Zanollo, D. Collavo, and T. Pozzan. Calcium and inositol phosphates in the activation of T cell-mediated cytotoxicity. *J. Exp. Med.* **166**:33-42 (1987).
 23. Mignery, G., T. C. Sudhof, K. Takei, and P. DeCamilli. Putative receptor for the inositol 1,4,5-trisphosphate similar to ryanodine receptor. *Nature (Lond.)* **342**:192-195 (1989).
 24. Walton, P. D., J. A. Airey, J. L. Sutko, C. F. Beck, G. A. Mignery, T. C. Sudhof, T. J. Deerinck, and M. H. Ellisman. Ryanodine and inositol trisphosphate receptors coexist in avian cerebellar Purkinje neurons. *J. Cell Biol.* **113**:1146-1157 (1991).
 25. Fasolato, C., P. Pizzo, and T. Pozzan. Receptor-mediated Ca²⁺ influx in PC12 cells: ATP and bradykinin activate two independent pathways. *J. Biol. Chem.* **265**:20351-20355 (1990).
 26. Fasolato, C., M. Zottini, E. Clementi, D. Zacchetti, J. Meldolesi, and T. Pozzan. Intracellular Ca²⁺ pools are distinguished by their turnover and mechanism of Ca²⁺ accumulation, storage and release. *J. Biol. Chem.* **266**:20159-20167 (1991).
 27. Scharff, O., B. Foder, and U. Skibsted. Hysteretic activation of the Ca²⁺ pump revealed by calcium transients in human red cells. *Biochim. Biophys. Acta* **730**:295-305 (1983).
 28. Thasturp, O., P. J. Cullen, B. K. Drobak, M. R. Hanley, and A. P. Dawson. Thapsigargin, a tumor promoter, discharges intracellular Ca²⁺ stores by specific inhibition of the endoplasmic reticulum Ca²⁺ ATPase. *Proc. Natl. Acad. Sci. USA* **87**:2466-2470 (1990).
 29. Lytton, J., M. Westlin, and M. R. Hanley. Thapsigargin inhibits the sarcoplasmic or endoplasmic reticulum Ca-ATPase family of calcium pumps. *J. Biol. Chem.* **266**:17067-17071 (1991).
 30. Takasago, T., T. Imagawa, K. Furukawa, T. Ogurusu, and M. Shigekawa. Regulation of the cardiac ryanodine receptor by protein kinase-dependent phosphorylation. *J. Biochem. (Tokyo)* **109**:163-170 (1991).
 31. Wang, J., and P. M. Best. Inactivation of the sarcoplasmic reticulum calcium channel by protein kinase. *Nature (Lond.)* **359**:739-741 (1992).

Send reprint requests to: Susan Treves, Institute of General Pathology, University of Ferrara, Via Borsari 46, 44100 Ferrara, Italy.
